Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Active Biotech to Sell North America, Japan TASQ Rights

March 21 (Bloomberg) -- Active Biotech AB expects to license the North American and Japanese rights to the TASQ prostate cancer drug before results are in from a late-stage clinical trial.

Active Biotech is also in talks to license its Anyara medicine for a form of kidney cancer and has no plans to seek more financing for its late-stage experimental drugs, Chief Executive Officer Tomas Leanderson said in an interview at a conference in Stockholm today.

Active Biotech, based in Lund, Sweden, partnered with Ipsen SA in April, giving the French drugmaker global commercial rights to TASQ, excluding North and South America and Japan. Data for TASQ, which is in late-stage clinical trials, will be presented in the second half of next year, Leanderson said.

A third late-stage trial for laquinimod, a treatment for multiple sclerosis, will probably be a stand-alone trial, not in combination with existing treatments, Leanderson said.

Teva Pharmaceutical Industries Ltd., Active Biotech’s partner on laquinimod, will start the new study in two or three months, Lesley Russell, head of the Israeli company’s research and development of global branded products, told investors at a presentation in New York on Feb. 27.

Teva and the U.S. Food and Drug Administration are in discussions about the trial design, which will involve a higher dosage than previous tests, Leanderson said.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.